TXN and glioblastoma: While clinical trials failed to develop a treatment targeting EGFRvIII-positive GBM, our findings underscore the value of investigating the highly aggressive mutant EGFRvIII as a novel potential vulnerability to implement TrX/GSH co-targeting in GBM.